ATE315935T1 - Verwendung von (3-(2-ethylphenyl)-5- methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten - Google Patents
Verwendung von (3-(2-ethylphenyl)-5- methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheitenInfo
- Publication number
- ATE315935T1 ATE315935T1 AT03720879T AT03720879T ATE315935T1 AT E315935 T1 ATE315935 T1 AT E315935T1 AT 03720879 T AT03720879 T AT 03720879T AT 03720879 T AT03720879 T AT 03720879T AT E315935 T1 ATE315935 T1 AT E315935T1
- Authority
- AT
- Austria
- Prior art keywords
- ethylphenyl
- subject
- triazole
- methoxyphenyl
- treatment
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- NAUNDFHXCIMBKS-UHFFFAOYSA-N 1-[3-(2-ethylphenyl)-5-methoxyphenyl]-1,2,4-triazole Chemical compound CCC1=CC=CC=C1C1=CC(OC)=CC(N2N=CN=C2)=C1 NAUNDFHXCIMBKS-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/137,699 US6797722B2 (en) | 2002-05-03 | 2002-05-03 | Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE315935T1 true ATE315935T1 (de) | 2006-02-15 |
Family
ID=29269138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03720879T ATE315935T1 (de) | 2002-05-03 | 2003-04-15 | Verwendung von (3-(2-ethylphenyl)-5- methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6797722B2 (https=) |
| EP (1) | EP1501505B1 (https=) |
| JP (1) | JP2005529904A (https=) |
| KR (1) | KR20040111491A (https=) |
| AT (1) | ATE315935T1 (https=) |
| AU (1) | AU2003224453A1 (https=) |
| CA (1) | CA2483904A1 (https=) |
| DE (1) | DE60303296T2 (https=) |
| DK (1) | DK1501505T3 (https=) |
| ES (1) | ES2257666T3 (https=) |
| MX (1) | MXPA04010785A (https=) |
| PL (1) | PL374252A1 (https=) |
| PT (1) | PT1501505E (https=) |
| TW (1) | TWI284532B (https=) |
| WO (1) | WO2003092681A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY142651A (en) * | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| WO2005077411A2 (en) * | 2004-02-10 | 2005-08-25 | Innate Pharma | Composition and method for the treatment of carcinoma |
| EP1921073A1 (en) | 2006-11-10 | 2008-05-14 | Laboratorios del Dr. Esteve S.A. | 1,2,4-Triazole derivatives as sigma receptor inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4379155A (en) * | 1979-06-11 | 1983-04-05 | Gruppo Lepetit S.P.A. | 3,5-Disubstituted-1H-1,2,4-triazole derivatives |
| JPS58126810A (ja) * | 1981-12-24 | 1983-07-28 | Kaken Pharmaceut Co Ltd | 抗炎症眼科用液剤およびその製法 |
| DE3808283A1 (de) * | 1988-03-12 | 1989-09-21 | Boehringer Ingelheim Kg | Neue 3,4,5-substituierte 4h-1,2,4-triazole, ihre herstellung und verwendung |
| US4895872A (en) * | 1989-03-15 | 1990-01-23 | Cetus Corporation | Immunosupressive analogues and derivatives of succinylacetone |
| US5273979A (en) * | 1991-08-01 | 1993-12-28 | Merck & Co., Inc. | C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent |
| US5189042A (en) * | 1991-08-22 | 1993-02-23 | Merck & Co. Inc. | Fluoromacrolides having immunosuppressive activity |
| US5484788A (en) * | 1993-03-26 | 1996-01-16 | Beth Israel Hospital Association | Buspirone as a systemic immunosuppressant |
| DE4320801A1 (de) * | 1993-06-23 | 1995-01-05 | Fahlberg List Pharma Gmbh | 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel |
| AU4385696A (en) * | 1996-01-18 | 1997-08-11 | Christian Gronhoj Larsen | Synthetic il-10 analogues |
| ATE298740T1 (de) * | 1997-04-04 | 2005-07-15 | Mitsubishi Pharma Corp | 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese |
| IT1292092B1 (it) * | 1997-06-05 | 1999-01-25 | Geange Ltd | Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali |
| EP1099695A1 (en) * | 1999-11-09 | 2001-05-16 | Laboratoire Theramex S.A. | 5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them |
-
2002
- 2002-05-03 US US10/137,699 patent/US6797722B2/en not_active Expired - Fee Related
-
2003
- 2003-04-15 PT PT03720879T patent/PT1501505E/pt unknown
- 2003-04-15 JP JP2004500865A patent/JP2005529904A/ja active Pending
- 2003-04-15 PL PL03374252A patent/PL374252A1/xx not_active Application Discontinuation
- 2003-04-15 KR KR10-2004-7015884A patent/KR20040111491A/ko not_active Ceased
- 2003-04-15 WO PCT/IT2003/000237 patent/WO2003092681A1/en not_active Ceased
- 2003-04-15 AT AT03720879T patent/ATE315935T1/de not_active IP Right Cessation
- 2003-04-15 EP EP03720879A patent/EP1501505B1/en not_active Expired - Lifetime
- 2003-04-15 AU AU2003224453A patent/AU2003224453A1/en not_active Abandoned
- 2003-04-15 ES ES03720879T patent/ES2257666T3/es not_active Expired - Lifetime
- 2003-04-15 DK DK03720879T patent/DK1501505T3/da active
- 2003-04-15 CA CA002483904A patent/CA2483904A1/en not_active Abandoned
- 2003-04-15 MX MXPA04010785A patent/MXPA04010785A/es active IP Right Grant
- 2003-04-15 DE DE60303296T patent/DE60303296T2/de not_active Expired - Fee Related
- 2003-04-22 TW TW092109389A patent/TWI284532B/zh not_active IP Right Cessation
-
2004
- 2004-03-30 US US10/812,308 patent/US20050026980A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60303296T2 (de) | 2006-08-17 |
| PL374252A1 (en) | 2005-10-03 |
| EP1501505B1 (en) | 2006-01-18 |
| EP1501505A1 (en) | 2005-02-02 |
| JP2005529904A (ja) | 2005-10-06 |
| CA2483904A1 (en) | 2003-11-13 |
| ES2257666T3 (es) | 2006-08-01 |
| PT1501505E (pt) | 2006-05-31 |
| US20050026980A1 (en) | 2005-02-03 |
| MXPA04010785A (es) | 2005-03-07 |
| DK1501505T3 (da) | 2006-05-22 |
| US6797722B2 (en) | 2004-09-28 |
| AU2003224453A1 (en) | 2003-11-17 |
| TW200418464A (en) | 2004-10-01 |
| DE60303296D1 (de) | 2006-04-06 |
| WO2003092681A1 (en) | 2003-11-13 |
| KR20040111491A (ko) | 2004-12-31 |
| TWI284532B (en) | 2007-08-01 |
| US20030207931A1 (en) | 2003-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20050089A2 (en) | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | |
| EA200500856A1 (ru) | Новые химические соединения | |
| BG108857A (en) | Glutaminyl based dpiv inhibitors | |
| LU93274I2 (fr) | Elotuzumab | |
| DE60135029D1 (de) | Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis | |
| ATE555803T1 (de) | Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen | |
| DE602004022061D1 (de) | Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen | |
| ATE403437T1 (de) | Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis | |
| WO2005059106A3 (en) | Interferon alpha antibodies and their uses | |
| DE69936785D1 (de) | Zellvermittelte genverabreichung durch verwendung von aus muskeln derivierten zellen zur behandlung der knochen-verwandten verletzung oder störung | |
| DE502005009201D1 (de) | Substituierte 1-propinoyl-piperazine mit affinität für den mglur5 rezeptor zur behandlung von schmerzzuständen | |
| ATE315935T1 (de) | Verwendung von (3-(2-ethylphenyl)-5- methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten | |
| ATE290857T1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| DE60308045D1 (de) | Pflanzenextrakte aus argyrolobium roseum zur behandlung von diabetes | |
| ATE352295T1 (de) | Verwendung von quinazolinen zur behandlung von t- zell vermittelten krankheiten | |
| DE602005016729D1 (de) | Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung | |
| ATE157010T1 (de) | Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen | |
| PT672124E (pt) | Utilizacao de uma sequencia de dna codificadora de uma proteina que degrada acido oxalico como gene de seleccao | |
| DE60213365D1 (de) | Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen | |
| WO2003097082A3 (en) | Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies | |
| ATE546154T1 (de) | Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung | |
| ATE245438T1 (de) | Verwendung von oligomerem matrixprotein aus knorpel zur behandlung von rheumatoider arthritis | |
| DE69936779D1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen | |
| ATE443763T1 (de) | Behandlungs- und prophylaxeverfahren | |
| WO2004099251A3 (en) | Compositions and methods for treatment of cryptococcosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1501505 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |